Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Vor Biopharma Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ENROLLMENT ON TRACK FOR PHASE 3 UPSTREAM MG TRIAL OF TELITACICEPT IN GENERALIZED MYASTHENIA GRAVIS PATIENTS WITH TOPLINE RESULTS ANTICIPATED IN 1H27 ENROLLMENT ONGOING FOR PHASE 3 UPSTREAM SJD OF TELITACICEPT IN PRIMARY SJGREN'S DISEASE PRO-FORMA CASH AND INVESTMENT BALANCE OF $514.5 MILLION EXPECTED TO PROVIDE RUNWAY INTO EARLY 2029 BOSTON, AUG. 11, 2026 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026, AND PROVIDED A CORPORATE UPDATE. WE CONTINUED TO MAKE MEANINGFUL PROGRESS IN 2026 WITH TELITACICEPT RECEIVING ITS FOURTH AND FIFTH COMMERCIAL APPROVALS IN CHINA FOR THE TREATMENT OF SJGREN'S DISEASE AND IGA NEPHROPATHY AND ITS PHASE 3 TELIGAN TRIAL IN IGA NEPHROPATHY BEING FEATURED IN THE NEW ENGLAND JOURNAL OF MEDICINE.

VOR BIO REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BOSTON, AUG. 03, 2026 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT, ON AUGUST 1, 2026, THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS GRANTED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 32,550 SHARES OF VOR BIO'S COMMON STOCK AND RESTRICTED STOCK UNITS (RSUS) REPRESENTING THE RIGHT TO RECEIVE AN AGGREGATE OF 6,900 SHARES OF VOR BIO'S COMMON STOCK TO 5 NEWLY HIRED EMPLOYEES. THE FOREGOING STOCK OPTIONS AND RSUS WERE GRANTED AS MATERIAL INDUCEMENTS TO EMPLOYMENT WITH VOR BIO IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4) AND WERE GRANTED UNDER THE VOR BIOPHARMA INC. 2023 INDUCEMENT PLAN (THE INDUCEMENT PLAN).

VOR BIO REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

BOSTON, JULY 07, 2026 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF DAVID ZACCARDELLI, PHARM.D., TO ITS BOARD OF DIRECTORS. WITH MORE THAN 20 YEARS OF BIOPHARMACEUTICAL LEADERSHIP EXPERIENCE, DR. ZACCARDELLI HAS SUCCESSFULLY BUILT AND LED COMPANIES THROUGH LATE-STAGE DEVELOPMENT, REGULATORY APPROVAL, AND COMMERCIAL LAUNCH.

VOR BIO APPOINTS DAVID ZACCARDELLI TO BOARD OF DIRECTORS

BOSTON, JULY 02, 2026 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT, ON JULY 1, 2026, THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS GRANTED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 71,200 SHARES OF VOR BIO'S COMMON STOCK AND RESTRICTED STOCK UNITS (RSUS) REPRESENTING THE RIGHT TO RECEIVE AN AGGREGATE OF 15,150 SHARES OF VOR BIO'S COMMON STOCK TO 7 NEWLY HIRED EMPLOYEES. THE FOREGOING STOCK OPTIONS AND RSUS WERE GRANTED AS MATERIAL INDUCEMENTS TO EMPLOYMENT WITH VOR BIO IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4) AND WERE GRANTED UNDER THE VOR BIOPHARMA INC. 2023 INDUCEMENT PLAN (THE INDUCEMENT PLAN).

FIRST REGULATORY APPROVAL FOR SJGREN'S DISEASE (SJD) FIRST AND ONLY APPROVED THERAPY FOR SJD IN CHINA APPROVAL BASED ON POSITIVE PHASE 3 RESULTS GENERATED BY COLLABORATOR REMEGEN DEMONSTRATING STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENTS IN BOTH ESSDAI AND ESSPRI SJD MARKS THE FIFTH INDICATION APPROVAL FOR TELITACICEPT BOSTON, JUNE 08, 2026 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, AND REMEGEN CO., LTD., (HKEX: 9995, SHA: 688331) TODAY ANNOUNCED THAT CHINA'S NATIONAL MEDICINAL PRODUCTS ADMINISTRATION (NMPA) HAS APPROVED TELITACICEPT FOR THE TREATMENT OF ADULT PATIENTS WITH SJD.

TELITACICEPT RECEIVES NMPA APPROVAL FOR THE TREATMENT OF SJGREN'S DISEASE IN CHINA

FIRST AND ONLY APPROVED BAFF/APRIL-TARGETING THERAPY FOR IGA NEPHROPATHY (IGAN) APPROVAL BASED ON POSITIVE INTERIM PHASE 3 TELIGAN RESULTS GENERATED BY COLLABORATOR REMEGEN AND RECENTLY PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE IGAN MARKS THE FOURTH INDICATION APPROVAL FOR TELITACICEPT BOSTON, JUNE 08, 2026 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, AND REMEGEN CO., LTD., (HKEX: 9995, SHA: 688331) TODAY ANNOUNCED THAT CHINA'S NATIONAL MEDICINAL PRODUCTS ADMINISTRATION (NMPA) HAS CONDITIONALLY APPROVED TELITACICEPT FOR THE TREATMENT OF ADULT PATIENTS WITH IGAN.

TELITACICEPT RECEIVES NMPA CONDITIONAL APPROVAL FOR THE TREATMENT OF IGA NEPHROPATHY IN CHINA

BOSTON, MASS., JUNE 01, 2026 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT, ON JUNE 1, 2026, THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS GRANTED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 61,050 SHARES OF VOR BIO'S COMMON STOCK AND RESTRICTED STOCK UNITS (RSUS) REPRESENTING THE RIGHT TO RECEIVE AN AGGREGATE OF 12,900 SHARES OF VOR BIO'S COMMON STOCK TO 10 NEWLY HIRED EMPLOYEES. THE FOREGOING STOCK OPTIONS AND RSUS WERE GRANTED AS MATERIAL INDUCEMENTS TO EMPLOYMENT WITH VOR BIO IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4) AND WERE GRANTED UNDER THE VOR BIOPHARMA INC. 2023 INDUCEMENT PLAN (THE INDUCEMENT PLAN).

BOSTON, MAY 28, 2026 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT IT WILL PROVIDE A CORPORATE UPDATE IN A FIRESIDE CHAT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK, NY.

VOR BIO TO PARTICIPATE IN THE 2026 JEFFERIES GLOBAL HEALTHCARE CONFERENCE

INTERIM ANALYSIS DEMONSTRATED A 55.0% RELATIVE REDUCTION IN PROTEINURIA VERSUS PLACEBO AT 39 WEEKS WITH EGFR REMAINING STABLE THROUGH TREATMENT RESULTS FURTHER SUPPORT THE POTENTIAL FOR TELITACICEPT TO BECOME A BEST-IN-CLASS DUAL BAFF/APRIL THERAPY ACROSS AUTOIMMUNE DISEASES BOSTON, MAY 14, 2026 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT RESULTS FROM THE PHASE 3 TELIGAN TRIAL EVALUATING TELITACICEPT IN IGA NEPHROPATHY IN CHINA SPONSORED BY ITS COLLABORATOR, REMEGEN CO., LTD., (HKEX: 9995, SHA: 688331), WERE PUBLISHED INTHE NEW ENGLAND JOURNAL OF MEDICINE (NEJM).

VOR BIO ANNOUNCES PUBLICATION OF INTERIM ANALYSIS OF TELIGAN, A CHINA PHASE 3 TRIAL OF TELITACICEPT IN IGA NEPHROPATHY, IN THE NEW ENGLAND JOURNAL OF MEDICINE

ENROLLMENT ON TRACK FOR PHASE 3 UPSTREAM MG TRIAL OF TELITACICEPT IN GENERALIZED MYASTHENIA GRAVIS PATIENTS WITH TOPLINE RESULTS ANTICIPATED IN 1H27 ENROLLMENT ONGOING FOR PHASE 3 UPSTREAM SJD OF TELITACICEPT IN PRIMARY SJGREN'S DISEASE CASH AND INVESTMENT BALANCE OF $491.5 MILLION AS OF MARCH 31, 2026 EXPECTED TO PROVIDE RUNWAY INTO EARLY 2029 BOSTON, MAY 13, 2026 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDED A CORPORATE UPDATE. WE HAD ANOTHER QUARTER OF SOLID EXECUTION FOR OUR TWO GLOBAL PHASE 3 PROGRAMS IN GENERALIZED MYASTHENIA GRAVIS AND PRIMARY SJGREN'S DISEASE, BOTH OF WHICH ARE PROGRESSING AS PLANNED, SAID JEAN-PAUL KRESS, M.D.

Vor Biopharma Inc.

VOR

Price

Financial Reports

No items found.

Press Releases

Vor Biopharma Inc.

VOR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

VOR